{
 "disease": "mesothelioma",
 "label": "Mesothelioma",
 "url": "https://usebiotransfer.org/disease/mesothelioma/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "cd6329b805aa",
  "targets": "fc063d2417b0"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "BAP1",
   "ensembl": "ENSG00000163930",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "NF2",
   "ensembl": "ENSG00000186575",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "SETD2",
   "ensembl": "ENSG00000181555",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "LATS2",
   "ensembl": "ENSG00000150457",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MSLN",
   "ensembl": "ENSG00000102854",
   "n_drug_entries": 5,
   "n_distinct_drugs": 5,
   "drugs": {
    "AMATUXIMAB": "PHASE_2",
    "ANETUMAB RAVTANSINE": "PHASE_2",
    "LMB-100": "PHASE_2",
    "RG-7600": "PHASE_1",
    "SS1(DSFV)-PE38": "PHASE_1_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CD274",
   "ensembl": "ENSG00000120217",
   "n_drug_entries": 13,
   "n_distinct_drugs": 13,
   "drugs": {
    "ADEBRELIMAB": "PHASE_3",
    "ATEZOLIZUMAB": "APPROVAL",
    "AVELUMAB": "APPROVAL",
    "BINTRAFUSP ALFA": "PHASE_3",
    "COSIBELIMAB": "APPROVAL",
    "DANBURSTOTUG": "PHASE_2",
    "DURVALUMAB": "APPROVAL",
    "ENVAFOLIMAB": "PHASE_3",
    "ERFONRILIMAB": "PHASE_3",
    "INCB-086550": "PHASE_2",
    "PACMILIMAB": "PHASE_2",
    "SOCAZOLIMAB": "PHASE_3",
    "SUGEMALIMAB": "APPROVAL"
   },
   "approved": [
    "ATEZOLIZUMAB",
    "AVELUMAB",
    "COSIBELIMAB",
    "DURVALUMAB",
    "SUGEMALIMAB"
   ],
   "n_approved": 5,
   "approved_for": {
    "ATEZOLIZUMAB": [
     "urothelial carcinoma",
     "non-small cell lung carcinoma",
     "breast cancer",
     "small cell lung carcinoma",
     "breast neoplasm",
     "transitional cell carcinoma"
    ],
    "AVELUMAB": [
     "Merkel cell skin cancer",
     "urothelial carcinoma",
     "neuroendocrine neoplasm"
    ],
    "COSIBELIMAB": [
     "head and neck squamous cell carcinoma"
    ],
    "DURVALUMAB": [
     "non-small cell lung carcinoma",
     "small cell lung carcinoma",
     "urothelial carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUGEMALIMAB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "PDCD1",
   "ensembl": "ENSG00000188389",
   "n_drug_entries": 26,
   "n_distinct_drugs": 26,
   "drugs": {
    "APL-501": "PHASE_2",
    "BALSTILIMAB": "PHASE_3",
    "BUDIGALIMAB": "PHASE_2_3",
    "CADONILIMAB": "PHASE_3",
    "CAMRELIZUMAB": "PHASE_3",
    "CEMIPLIMAB": "APPROVAL",
    "CETRELIMAB": "PHASE_3",
    "CS-1003": "PHASE_3",
    "DOSTARLIMAB": "APPROVAL",
    "FINOTONLIMAB": "PHASE_3",
    "LOMVASTOMIG": "PHASE_2",
    "NIVOLUMAB": "APPROVAL",
    "PEMBROLIZUMAB": "APPROVAL",
    "PENPULIMAB": "PHASE_3",
    "PIDILIZUMAB": "PHASE_2",
    "PIMIVALIMAB": "PHASE_2",
    "PUCOTENLIMAB": "PHASE_3",
    "RETIFANLIMAB": "APPROVAL",
    "SASANLIMAB": "PHASE_3",
    "SERPLULIMAB": "APPROVAL",
    "SINTILIMAB": "APPROVAL",
    "SPARTALIZUMAB": "PHASE_3",
    "TEBOTELIMAB": "PHASE_2_3",
    "TISLELIZUMAB": "APPROVAL",
    "TORIPALIMAB": "APPROVAL",
    "ZIMBERELIMAB": "PHASE_3"
   },
   "approved": [
    "CEMIPLIMAB",
    "DOSTARLIMAB",
    "NIVOLUMAB",
    "PEMBROLIZUMAB",
    "RETIFANLIMAB",
    "SERPLULIMAB",
    "SINTILIMAB",
    "TISLELIZUMAB",
    "TORIPALIMAB"
   ],
   "n_approved": 9,
   "approved_for": {
    "CEMIPLIMAB": [
     "squamous cell carcinoma",
     "basal cell carcinoma",
     "cutaneous squamous cell carcinoma",
     "cervical cancer"
    ],
    "DOSTARLIMAB": [
     "endometrial cancer",
     "endometrial neoplasm"
    ],
    "NIVOLUMAB": [
     "head and neck cancer",
     "pleural mesothelioma",
     "gastric cancer",
     "melanoma",
     "non-small cell lung carcinoma",
     "renal cell carcinoma",
     "transitional cell carcinoma",
     "colorectal neoplasm",
     "Hodgkins lymphoma",
     "mesothelioma",
     "head and neck squamous cell carcinoma",
     "classic Hodgkin lymphoma",
     "metastatic melanoma"
    ],
    "PEMBROLIZUMAB": [
     "melanoma",
     "metastatic melanoma",
     "endometrium neoplasm",
     "head and neck squamous cell carcinoma",
     "transitional cell carcinoma",
     "renal cell carcinoma",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma"
    ],
    "RETIFANLIMAB": [
     "neuroendocrine carcinoma",
     "Merkel cell skin cancer",
     "squamous cell carcinoma"
    ],
    "SERPLULIMAB": [
     "esophageal squamous cell carcinoma",
     "non-small cell lung carcinoma",
     "small cell lung carcinoma"
    ],
    "SINTILIMAB": [
     "Hodgkins lymphoma"
    ],
    "TISLELIZUMAB": [
     "esophageal cancer",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma",
     "adenocarcinoma",
     "esophageal squamous cell carcinoma",
     "gastric neoplasm"
    ],
    "TORIPALIMAB": [
     "melanoma",
     "nasopharyngeal carcinoma",
     "urothelial carcinoma",
     "esophageal squamous cell carcinoma",
     "Niemann-Pick disease type B"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CTLA4",
   "ensembl": "ENSG00000163599",
   "n_drug_entries": 6,
   "n_distinct_drugs": 6,
   "drugs": {
    "CADONILIMAB": "PHASE_3",
    "ERFONRILIMAB": "PHASE_3",
    "IPILIMUMAB": "APPROVAL",
    "QUAVONLIMAB": "PHASE_3",
    "TREMELIMUMAB": "APPROVAL",
    "ZALIFRELIMAB": "PHASE_2"
   },
   "approved": [
    "IPILIMUMAB",
    "TREMELIMUMAB"
   ],
   "n_approved": 2,
   "approved_for": {
    "IPILIMUMAB": [
     "metastatic melanoma",
     "melanoma",
     "colorectal neoplasm",
     "non-small cell lung carcinoma",
     "malignant mesothelioma",
     "renal cell carcinoma"
    ],
    "TREMELIMUMAB": [
     "non-small cell lung carcinoma",
     "hepatocellular carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    }
   ]
  },
  {
   "symbol": "VEGFA",
   "ensembl": "ENSG00000112715",
   "n_drug_entries": 14,
   "n_distinct_drugs": 13,
   "drugs": {
    "ABICIPAR PEGOL": "APPROVAL",
    "AFLIBERCEPT": "APPROVAL",
    "BEVACIZUMAB": "APPROVAL",
    "BEVACIZUMAB GAMMA": "APPROVAL",
    "BEVASIRANIB": "PHASE_3",
    "BROLUCIZUMAB": "APPROVAL",
    "CONBERCEPT": "PHASE_3",
    "FARICIMAB": "APPROVAL",
    "MUPARFOSTAT": "PHASE_3",
    "PEGAPTANIB": "APPROVAL",
    "PEGAPTANIB OCTASODIUM": "PHASE_3",
    "RANIBIZUMAB": "APPROVAL",
    "VANUCIZUMAB": "PHASE_2"
   },
   "approved": [
    "ABICIPAR PEGOL",
    "AFLIBERCEPT",
    "BEVACIZUMAB",
    "BEVACIZUMAB GAMMA",
    "BROLUCIZUMAB",
    "FARICIMAB",
    "PEGAPTANIB",
    "RANIBIZUMAB"
   ],
   "n_approved": 8,
   "approved_for": {
    "ABICIPAR PEGOL": [
     "ocular vascular disorder"
    ],
    "AFLIBERCEPT": [
     "macular degeneration",
     "retinal vein occlusion",
     "colorectal cancer",
     "choroidal neovascularization",
     "diabetic macular edema",
     "myopia",
     "edema",
     "metastatic colorectal cancer",
     "macular retinal edema",
     "macrovascular complications of diabetes",
     "wet macular degeneration",
     "colorectal neoplasm",
     "pathological myopia",
     "diabetic retinopathy",
     "colorectal adenocarcinoma",
     "ocular vascular disorder"
    ],
    "BEVACIZUMAB": [
     "colorectal cancer",
     "non-small cell squamous lung carcinoma",
     "breast cancer",
     "cervical cancer",
     "non-small cell lung carcinoma",
     "colorectal adenocarcinoma",
     "renal cell carcinoma",
     "colonic neoplasm",
     "glioblastoma",
     "metastatic colorectal cancer",
     "breast neoplasm",
     "peritoneal neoplasm",
     "colorectal neoplasm",
     "fallopian tube neoplasm",
     "ovarian neoplasm",
     "fallopian tube carcinoma",
     "ocular vascular disorder"
    ],
    "BEVACIZUMAB GAMMA": [
     "wet macular degeneration"
    ],
    "BROLUCIZUMAB": [
     "macular degeneration",
     "wet macular degeneration",
     "ocular vascular disorder"
    ],
    "FARICIMAB": [
     "diabetic macular edema",
     "wet macular degeneration",
     "macular retinal edema",
     "cystoid macular edema",
     "ocular vascular disorder"
    ],
    "PEGAPTANIB": [
     "wet macular degeneration",
     "macular degeneration"
    ],
    "RANIBIZUMAB": [
     "macular degeneration",
     "hereditary hemorrhagic telangiectasia",
     "macular retinal edema",
     "diabetic retinopathy",
     "wet macular degeneration",
     "macrovascular complications of diabetes",
     "myopia",
     "pathological myopia",
     "choroidal neovascularization",
     "retinal vein occlusion",
     "ocular vascular disorder"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "ALK",
   "ensembl": "ENSG00000171094",
   "n_drug_entries": 12,
   "n_distinct_drugs": 11,
   "drugs": {
    "ALECTINIB": "APPROVAL",
    "ASP-3026": "PHASE_1",
    "BRIGATINIB": "APPROVAL",
    "CEP-37440": "PHASE_1",
    "CERITINIB": "APPROVAL",
    "CONTELTINIB": "PHASE_1_2",
    "CRIZOTINIB": "APPROVAL",
    "ENSARTINIB": "PHASE_3",
    "ENTRECTINIB": "APPROVAL",
    "LORLATINIB": "APPROVAL",
    "PLB1003": "PHASE_1"
   },
   "approved": [
    "ALECTINIB",
    "BRIGATINIB",
    "CERITINIB",
    "CRIZOTINIB",
    "ENTRECTINIB",
    "LORLATINIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "ALECTINIB": [
     "non-small cell lung carcinoma"
    ],
    "BRIGATINIB": [
     "non-small cell lung carcinoma",
     "anaplastic large cell lymphoma"
    ],
    "CERITINIB": [
     "non-small cell lung carcinoma"
    ],
    "CRIZOTINIB": [
     "non-small cell lung carcinoma"
    ],
    "ENTRECTINIB": [
     "non-small cell lung carcinoma"
    ],
    "LORLATINIB": [
     "lymphoma",
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Phase 1 Clinical"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "mesothelin": {
    "n": 40,
    "n_observational": 4,
    "n_active": 11,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05568680",
      "title": "SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06051695",
      "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06196294",
      "title": "GPC3/Mesothelin-CAR-\u03b3\u03b4T Cells Against Cancers",
      "status": "RECRUITING",
      "last_update": "2024-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06756035",
      "title": "CT-95 in Advanced Cancers Associated With Mesothelin Expression",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06885697",
      "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07510815",
      "title": "Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006981",
      "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00066651",
      "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00325494",
      "title": "A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00585845",
      "title": "Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment",
      "status": "TERMINATED",
      "last_update": "2009-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00738582",
      "title": "An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2022-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01355965",
      "title": "Autologous Redirected RNA Meso-CIR T Cells",
      "status": "COMPLETED",
      "last_update": "2017-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01413451",
      "title": "Amatuximab for High Mesothelin Cancers",
      "status": "TERMINATED",
      "last_update": "2019-12-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01521325",
      "title": "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers",
      "status": "COMPLETED",
      "last_update": "2016-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01583686",
      "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2019-10-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01675765",
      "title": "Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2020-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159716",
      "title": "CART-meso in Mesothelin Expressing Cancers",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02357147",
      "title": "Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)",
      "status": "TERMINATED",
      "last_update": "2020-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02414269",
      "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02485119",
      "title": "Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2018-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02580747",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso",
      "status": "UNKNOWN",
      "last_update": "2015-10-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02610140",
      "title": "Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)",
      "status": "COMPLETED",
      "last_update": "2020-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02639091",
      "title": "Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-11-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02798536",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2022-08-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03054298",
      "title": "CAR T Cells in Mesothelin Expressing Cancers",
      "status": "COMPLETED",
      "last_update": "2025-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126630",
      "title": "Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03436732",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2019-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03507452",
      "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin",
      "status": "COMPLETED",
      "last_update": "2023-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03608618",
      "title": "Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2021-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03644550",
      "title": "Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03907852",
      "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03926143",
      "title": "A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies",
      "status": "TERMINATED",
      "last_update": "2023-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034238",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-08-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04489862",
      "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-07-28",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04577326",
      "title": "Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04840615",
      "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05375825",
      "title": "Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin",
      "status": "WITHDRAWN",
      "last_update": "2024-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05451849",
      "title": "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer",
      "status": "TERMINATED",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06256055",
      "title": "Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07420010",
      "title": "An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 12,
     "n_observational": 0,
     "n_active": 6,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT06051695",
       "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
       "status": "RECRUITING",
       "last_update": "2026-06-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06196294",
       "title": "GPC3/Mesothelin-CAR-\u03b3\u03b4T Cells Against Cancers",
       "status": "RECRUITING",
       "last_update": "2024-06-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06885697",
       "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07510815",
       "title": "Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma",
       "status": "RECRUITING",
       "last_update": "2026-04-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01355965",
       "title": "Autologous Redirected RNA Meso-CIR T Cells",
       "status": "COMPLETED",
       "last_update": "2017-09-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01583686",
       "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer",
       "status": "TERMINATED",
       "last_update": "2019-10-14",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02159716",
       "title": "CART-meso in Mesothelin Expressing Cancers",
       "status": "COMPLETED",
       "last_update": "2025-06-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02414269",
       "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02580747",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso",
       "status": "UNKNOWN",
       "last_update": "2015-10-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03054298",
       "title": "CAR T Cells in Mesothelin Expressing Cancers",
       "status": "COMPLETED",
       "last_update": "2025-04-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04489862",
       "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2020-07-28",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04577326",
       "title": "Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "mesothelin",
     "MSLN",
     "anetumab",
     "amatuximab",
     "LMB-100",
     "ofatumumab"
    ]
   },
   "PD-1": {
    "n": 92,
    "n_observational": 4,
    "n_active": 37,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT03556228",
      "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03760575",
      "title": "Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04400539",
      "title": "The IMmunotherapy Pleural 5-ALA PDT",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665206",
      "title": "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05579366",
      "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05627960",
      "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2022-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05647265",
      "title": "Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05732831",
      "title": "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05944237",
      "title": "HTL0039732 in Participants With Advanced Solid Tumours",
      "status": "RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06840834",
      "title": "Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07121374",
      "title": "NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study",
      "status": "RECRUITING",
      "last_update": "2025-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07234058",
      "title": "Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07532902",
      "title": "A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07563738",
      "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02399371",
      "title": "Pembrolizumab in Treating Patients With Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02414269",
      "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460224",
      "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",
      "status": "COMPLETED",
      "last_update": "2022-02-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02497508",
      "title": "Nivolumab in Patients With Recurrent Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2017-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "status": "UNKNOWN",
      "last_update": "2022-04-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02661100",
      "title": "A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients",
      "status": "WITHDRAWN",
      "last_update": "2016-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02707666",
      "title": "A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02716272",
      "title": "Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients",
      "status": "COMPLETED",
      "last_update": "2021-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02758587",
      "title": "Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)",
      "status": "UNKNOWN",
      "last_update": "2018-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02784171",
      "title": "Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2024-12-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02812875",
      "title": "A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",
      "status": "COMPLETED",
      "last_update": "2020-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02899299",
      "title": "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02903914",
      "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959463",
      "title": "Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02991482",
      "title": "PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03048474",
      "title": "Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2021-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03063450",
      "title": "CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-04-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126630",
      "title": "Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03175172",
      "title": "Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)",
      "status": "TERMINATED",
      "last_update": "2019-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03233724",
      "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",
      "status": "TERMINATED",
      "last_update": "2023-05-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277352",
      "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03393858",
      "title": "Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-02-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03502746",
      "title": "Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03546426",
      "title": "Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03644550",
      "title": "Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654833",
      "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03852823",
      "title": "Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours",
      "status": "UNKNOWN",
      "last_update": "2021-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03881488",
      "title": "Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03907852",
      "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03918252",
      "title": "Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03920839",
      "title": "INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)",
      "status": "WITHDRAWN",
      "last_update": "2020-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04013334",
      "title": "MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2022-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04040231",
      "title": "Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04056026",
      "title": "A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2019-09-23",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04153565",
      "title": "A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)",
      "status": "COMPLETED",
      "last_update": "2025-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04162015",
      "title": "A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04166734",
      "title": "Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2026-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04177953",
      "title": "Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery",
      "status": "COMPLETED",
      "last_update": "2025-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04201145",
      "title": "Pembrolizumab + Defactinib In Pleural Mesothelioma",
      "status": "WITHDRAWN",
      "last_update": "2020-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04242199",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04272034",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04287829",
      "title": "Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04300244",
      "title": "Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04301011",
      "title": "Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04334759",
      "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-01-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04489862",
      "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-07-28",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04672434",
      "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04713761",
      "title": "Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2021-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04897022",
      "title": "A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913337",
      "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04914897",
      "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05041062",
      "title": "A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2024-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05070247",
      "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-01-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05071014",
      "title": "A Study of Pembrolizumab and Cryoablation in People With Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2023-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05136677",
      "title": "A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants",
      "status": "COMPLETED",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05238883",
      "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05425576",
      "title": "OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05582031",
      "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers",
      "status": "WITHDRAWN",
      "last_update": "2023-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05714553",
      "title": "NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours",
      "status": "TERMINATED",
      "last_update": "2026-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034860",
      "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06097728",
      "title": "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06155279",
      "title": "Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06318286",
      "title": "Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07131345",
      "title": "Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02414269",
       "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04489862",
       "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2020-07-28",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "nivolumab",
     "Opdivo",
     "pembrolizumab",
     "Keytruda"
    ]
   },
   "CTLA-4": {
    "n": 24,
    "n_observational": 2,
    "n_active": 12,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04665206",
      "title": "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05647265",
      "title": "Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07121374",
      "title": "NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study",
      "status": "RECRUITING",
      "last_update": "2025-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07532902",
      "title": "A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07563738",
      "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01649024",
      "title": "A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2012-07-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01655888",
      "title": "The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2012-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01843374",
      "title": "Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02716272",
      "title": "Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients",
      "status": "COMPLETED",
      "last_update": "2021-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02899299",
      "title": "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03048474",
      "title": "Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2021-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03907852",
      "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03918252",
      "title": "Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04300244",
      "title": "Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04334759",
      "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-01-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04840615",
      "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05041062",
      "title": "A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2024-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05136677",
      "title": "A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants",
      "status": "COMPLETED",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06097728",
      "title": "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07131345",
      "title": "Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab",
     "Yervoy"
    ]
   },
   "PD-L1": {
    "n": 43,
    "n_observational": 0,
    "n_active": 15,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03556228",
      "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04996017",
      "title": "Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)",
      "status": "RECRUITING",
      "last_update": "2025-03-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05001880",
      "title": "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05627960",
      "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2022-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05765084",
      "title": "Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05932199",
      "title": "Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05944237",
      "title": "HTL0039732 in Participants With Advanced Solid Tumours",
      "status": "RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07330271",
      "title": "PTC-Guided Therapy for Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02141347",
      "title": "Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2018-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460224",
      "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",
      "status": "COMPLETED",
      "last_update": "2022-02-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02588131",
      "title": "A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)",
      "status": "UNKNOWN",
      "last_update": "2015-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02592551",
      "title": "MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2022-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02812875",
      "title": "A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",
      "status": "COMPLETED",
      "last_update": "2020-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02899195",
      "title": "Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2023-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02903914",
      "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02991482",
      "title": "PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03063450",
      "title": "CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-04-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03075527",
      "title": "A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228537",
      "title": "Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03233724",
      "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",
      "status": "TERMINATED",
      "last_update": "2023-05-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03546426",
      "title": "Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654833",
      "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03762018",
      "title": "BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03786419",
      "title": "A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma",
      "status": "WITHDRAWN",
      "last_update": "2021-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03881488",
      "title": "Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03983954",
      "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04115111",
      "title": "Diadem to Investigate the Activity and Safety of Durvalumab",
      "status": "COMPLETED",
      "last_update": "2023-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04153565",
      "title": "A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)",
      "status": "COMPLETED",
      "last_update": "2025-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04334759",
      "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-01-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04480372",
      "title": "SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II",
      "status": "COMPLETED",
      "last_update": "2024-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04914897",
      "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940637",
      "title": "UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC",
      "status": "UNKNOWN",
      "last_update": "2023-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05005429",
      "title": "Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05380713",
      "title": "......SMARTEST Trial......",
      "status": "COMPLETED",
      "last_update": "2025-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06090318",
      "title": "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss",
      "status": "WITHDRAWN",
      "last_update": "2023-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-L1",
     "atezolizumab",
     "durvalumab"
    ]
   },
   "VEGF": {
    "n": 20,
    "n_observational": 3,
    "n_active": 6,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05001880",
      "title": "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05579366",
      "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06543069",
      "title": "Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM",
      "status": "RECRUITING",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06840834",
      "title": "Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00027703",
      "title": "Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2014-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00137826",
      "title": "Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2011-12-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295503",
      "title": "Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2020-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00407459",
      "title": "Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2011-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00604461",
      "title": "Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)",
      "status": "TERMINATED",
      "last_update": "2017-03-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00651456",
      "title": "Mesothelioma Avastin Plus Pemetrexed-cisplatin Study",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00668499",
      "title": "A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma",
      "status": "WITHDRAWN",
      "last_update": "2014-05-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03502746",
      "title": "Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03560973",
      "title": "A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654833",
      "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03762018",
      "title": "BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430842",
      "title": "Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05930665",
      "title": "Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2024-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07514793",
      "title": "Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "VEGF",
     "bevacizumab",
     "ramucirumab"
    ]
   },
   "FAP": {
    "n": 7,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06503146",
      "title": "18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06710756",
      "title": "Lead-212 PSV359 Therapy for Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06790082",
      "title": "The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07510815",
      "title": "Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01722149",
      "title": "Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2019-08-07",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06451536",
      "title": "Ga-68 FAPI PET Before Immunotherapy",
      "status": "UNKNOWN",
      "last_update": "2024-06-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07705074",
      "title": "FAPI PET Imaging - An Exploratory Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07510815",
       "title": "Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma",
       "status": "RECRUITING",
       "last_update": "2026-04-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01722149",
       "title": "Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma",
       "status": "COMPLETED",
       "last_update": "2019-08-07",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "FAP",
     "fibroblast activation protein"
    ]
   },
   "WT1": {
    "n": 8,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05765084",
      "title": "Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020579",
      "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398138",
      "title": "Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2016-03-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01265433",
      "title": "Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy",
      "status": "COMPLETED",
      "last_update": "2024-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01291420",
      "title": "Dendritic Cell Vaccination for Patients with Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-12-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02408016",
      "title": "Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2021-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02649829",
      "title": "Autologous Dendritic Cell Vaccination in Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-04-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04040231",
      "title": "Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02408016",
       "title": "Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma",
       "status": "TERMINATED",
       "last_update": "2021-09-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "WT1",
     "galinpepimut"
    ]
   }
  },
  "by_drug": {
   "ALRIZOMADLIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06654050",
      "title": "Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma",
      "status": "WITHDRAWN",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AMATUXIMAB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00325494",
      "title": "A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00738582",
      "title": "An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2022-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01413451",
      "title": "Amatuximab for High Mesothelin Cancers",
      "status": "TERMINATED",
      "last_update": "2019-12-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01521325",
      "title": "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers",
      "status": "COMPLETED",
      "last_update": "2016-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02357147",
      "title": "Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)",
      "status": "TERMINATED",
      "last_update": "2020-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ANETUMAB RAVTANSINE": {
    "n": 5,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02485119",
      "title": "Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2018-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02610140",
      "title": "Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)",
      "status": "COMPLETED",
      "last_update": "2020-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02639091",
      "title": "Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-11-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126630",
      "title": "Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03926143",
      "title": "A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies",
      "status": "TERMINATED",
      "last_update": "2023-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ATEZOLIZUMAB": {
    "n": 14,
    "n_observational": 0,
    "n_active": 7,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04996017",
      "title": "Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)",
      "status": "RECRUITING",
      "last_update": "2025-03-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05001880",
      "title": "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05765084",
      "title": "Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05944237",
      "title": "HTL0039732 in Participants With Advanced Solid Tumours",
      "status": "RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228537",
      "title": "Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654833",
      "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03762018",
      "title": "BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03786419",
      "title": "A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma",
      "status": "WITHDRAWN",
      "last_update": "2021-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04480372",
      "title": "SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II",
      "status": "COMPLETED",
      "last_update": "2024-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06090318",
      "title": "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss",
      "status": "WITHDRAWN",
      "last_update": "2023-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AVELUMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03399552",
      "title": "Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2023-10-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475953",
      "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-03-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04328844",
      "title": "A Study to Assess a PI3K\u03b4 Inhibitor (IOA-244) in Patients With Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BEVACIZUMAB": {
    "n": 15,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05001880",
      "title": "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05579366",
      "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06543069",
      "title": "Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM",
      "status": "RECRUITING",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00027703",
      "title": "Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2014-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00137826",
      "title": "Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2011-12-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295503",
      "title": "Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2020-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00407459",
      "title": "Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2011-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00604461",
      "title": "Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)",
      "status": "TERMINATED",
      "last_update": "2017-03-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00651456",
      "title": "Mesothelioma Avastin Plus Pemetrexed-cisplatin Study",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654833",
      "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03762018",
      "title": "BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430842",
      "title": "Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05930665",
      "title": "Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2024-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07514793",
      "title": "Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BEVACIZUMAB GAMMA": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05001880",
      "title": "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BINTRAFUSP ALFA": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05005429",
      "title": "Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BUDIGALIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03000257",
      "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03071757",
      "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CADONILIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05930665",
      "title": "Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2024-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06416930",
      "title": "Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEMIPLIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07234058",
      "title": "Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COSIBELIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DOSTARLIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03654833",
      "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940637",
      "title": "UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC",
      "status": "UNKNOWN",
      "last_update": "2023-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DURVALUMAB": {
    "n": 12,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05932199",
      "title": "Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02141347",
      "title": "Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2018-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02588131",
      "title": "A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)",
      "status": "UNKNOWN",
      "last_update": "2015-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02592551",
      "title": "MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2022-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02899195",
      "title": "Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2023-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03075527",
      "title": "A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03983954",
      "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04115111",
      "title": "Diadem to Investigate the Activity and Safety of Durvalumab",
      "status": "COMPLETED",
      "last_update": "2023-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04334759",
      "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-01-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05380713",
      "title": "......SMARTEST Trial......",
      "status": "COMPLETED",
      "last_update": "2025-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IPILIMUMAB": {
    "n": 19,
    "n_observational": 2,
    "n_active": 10,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04665206",
      "title": "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05647265",
      "title": "Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07121374",
      "title": "NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study",
      "status": "RECRUITING",
      "last_update": "2025-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07532902",
      "title": "A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07563738",
      "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02716272",
      "title": "Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients",
      "status": "COMPLETED",
      "last_update": "2021-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02899299",
      "title": "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03048474",
      "title": "Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2021-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03907852",
      "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03918252",
      "title": "Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04300244",
      "title": "Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04334759",
      "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-01-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04840615",
      "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05041062",
      "title": "A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2024-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05136677",
      "title": "A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants",
      "status": "COMPLETED",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06097728",
      "title": "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LMB-100": {
    "n": 6,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT02798536",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2022-08-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03436732",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2019-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03644550",
      "title": "Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034238",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-08-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04840615",
      "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05375825",
      "title": "Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin",
      "status": "WITHDRAWN",
      "last_update": "2024-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NIVOLUMAB": {
    "n": 31,
    "n_observational": 3,
    "n_active": 13,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04400539",
      "title": "The IMmunotherapy Pleural 5-ALA PDT",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665206",
      "title": "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05647265",
      "title": "Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07121374",
      "title": "NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study",
      "status": "RECRUITING",
      "last_update": "2025-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07532902",
      "title": "A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07563738",
      "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02497508",
      "title": "Nivolumab in Patients With Recurrent Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2017-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "status": "UNKNOWN",
      "last_update": "2022-04-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02716272",
      "title": "Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients",
      "status": "COMPLETED",
      "last_update": "2021-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02899299",
      "title": "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03048474",
      "title": "Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2021-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03063450",
      "title": "CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-04-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03502746",
      "title": "Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03907852",
      "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03918252",
      "title": "Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04013334",
      "title": "MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2022-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04040231",
      "title": "Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04162015",
      "title": "A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04177953",
      "title": "Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery",
      "status": "COMPLETED",
      "last_update": "2025-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04300244",
      "title": "Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04334759",
      "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-01-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05041062",
      "title": "A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2024-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05136677",
      "title": "A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants",
      "status": "COMPLETED",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034860",
      "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06097728",
      "title": "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PEMBROLIZUMAB": {
    "n": 45,
    "n_observational": 0,
    "n_active": 17,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03556228",
      "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03760575",
      "title": "Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05579366",
      "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05627960",
      "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2022-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05732831",
      "title": "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02399371",
      "title": "Pembrolizumab in Treating Patients With Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02414269",
      "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02661100",
      "title": "A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients",
      "status": "WITHDRAWN",
      "last_update": "2016-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02707666",
      "title": "A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02758587",
      "title": "Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)",
      "status": "UNKNOWN",
      "last_update": "2018-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02784171",
      "title": "Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2024-12-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02903914",
      "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959463",
      "title": "Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02991482",
      "title": "PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126630",
      "title": "Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03175172",
      "title": "Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)",
      "status": "TERMINATED",
      "last_update": "2019-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03233724",
      "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",
      "status": "TERMINATED",
      "last_update": "2023-05-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277352",
      "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03393858",
      "title": "Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-02-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03546426",
      "title": "Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03644550",
      "title": "Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654833",
      "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03881488",
      "title": "Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04056026",
      "title": "A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2019-09-23",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04153565",
      "title": "A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)",
      "status": "COMPLETED",
      "last_update": "2025-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04166734",
      "title": "Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2026-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04201145",
      "title": "Pembrolizumab + Defactinib In Pleural Mesothelioma",
      "status": "WITHDRAWN",
      "last_update": "2020-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04287829",
      "title": "Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04301011",
      "title": "Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04897022",
      "title": "A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913337",
      "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04914897",
      "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05070247",
      "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-01-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05071014",
      "title": "A Study of Pembrolizumab and Cryoablation in People With Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2023-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05425576",
      "title": "OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05714553",
      "title": "NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours",
      "status": "TERMINATED",
      "last_update": "2026-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06155279",
      "title": "Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06318286",
      "title": "Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RETIFANLIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03920839",
      "title": "INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)",
      "status": "WITHDRAWN",
      "last_update": "2020-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SINTILIMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05188859",
      "title": "First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2025-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06543069",
      "title": "Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM",
      "status": "RECRUITING",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07330271",
      "title": "PTC-Guided Therapy for Peritoneal Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SPARTALIZUMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02460224",
      "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",
      "status": "COMPLETED",
      "last_update": "2022-02-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03393858",
      "title": "Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2024-02-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04672434",
      "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SS1(DSFV)-PE38": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00006981",
      "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00066651",
      "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01362790",
      "title": "SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2019-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01445392",
      "title": "SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2018-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TISLELIZUMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05238883",
      "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05582031",
      "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers",
      "status": "WITHDRAWN",
      "last_update": "2023-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TORIPALIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04713761",
      "title": "Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2021-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TREMELIMUMAB": {
    "n": 9,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05932199",
      "title": "Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01649024",
      "title": "A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2012-07-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01655888",
      "title": "The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma",
      "status": "UNKNOWN",
      "last_update": "2012-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01843374",
      "title": "Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02141347",
      "title": "Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2018-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02588131",
      "title": "A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)",
      "status": "UNKNOWN",
      "last_update": "2015-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02592551",
      "title": "MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2022-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03075527",
      "title": "A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma",
      "status": "TERMINATED",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05380713",
      "title": "......SMARTEST Trial......",
      "status": "COMPLETED",
      "last_update": "2025-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZIMBERELIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06790706",
      "title": "IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}